FDA+ channel feed – Endpoints News

FDA+ channel feed

Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote

6 years ago

Patient experience data: Sanofi researchers call for more consistency from FDA

6 years ago

In reversal, NICE backs Rubraca after Clovis agrees to a price cut

6 years ago

Rare disease clinical trials: FDA awards $15M in grants

6 years ago

FDA approves drug for rare condition that triggers intense pain from light exposure

6 years ago

Is FDA too lax with its drug approval standards? Senior FDA officials discuss

6 years ago

Differin maker Galderma wins FDA approval for a new retinoid for acne

6 years ago

Gilead scores PrEP approval for Descovy — kicking off marketing push before Truvada generics swarm

6 years ago

In an unusual move, ICER rescinds draft report on JAK drugs for rheumatoid arthritis to revise its modeling approach

6 years ago

When can RWE translate into credible evidence? EMA officials discuss

6 years ago

Trump will pick Stephen Hahn as his next FDA commissioner — reports

6 years ago

Former FDA chief Califf is set to work full time for Alphabet

6 years ago

Patient-focused drug development: New FDA draft guidance delves into what’s important

6 years ago

J&J's embattled Invokana gets a boost as FDA expands label

6 years ago

FDA clears shorter treatment regimen for AbbVie's hep C treatment, Mavyret. Will patients benefit?

6 years ago

Another big biopharma merger runs into another snag at the FTC. What now?

6 years ago

OND reorganization moves forward

6 years ago

Republicans rebuke Pelosi drug pricing bill

6 years ago

FDA endorses Bavarian Nordic's monkeypox vaccine, marking world's first approval

6 years ago

Novartis accuses 2 AveXis founders of altering data, stonewalling probe — but ex-CSO blasts back

6 years ago

Embattled AMAG braces for October FDA Makena adcom, but it need not worry — analyst

6 years ago

GW Pharma's cannabis-derived epilepsy medicine makes the cut in the European Union

6 years ago

FDA puts the brakes on a rare disease biotech’s PhIII as regulators wait for an update — shares crumble

6 years ago

Intrexon unit pushes back against claims its GM mosquitoes are making disease-friendly mutants

6 years ago

First page Previous page 138 139 140141142 143 144 Next page Last page